News
Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease
Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI).
The landmark initiative will use Cambridge Cognition’s technology to identify the cognitive profile of Parkinson’s Disease patients within the study. This effort aims to enhance understanding of the underlying mechanisms of the disease, demystify its origins and identify interventions that could halt its progression.
The PPMI study targets individuals diagnosed with Parkinson’s disease within a two-year window, shedding light on the disease’s early stages and the neurological changes it induces. To characterize patients in this crucial research, PPMI will use 5,000 CANTAB® cognitive assessments from Cambridge Cognition.
CANTAB® digital assessments provide valid, sensitive, and objective insights into cognitive functions. With user-friendly tasks designed for clinic and home settings, these assessments ensure active participant engagement and enable sensitive data collection crucial for understanding Parkinson’s disease progression.
Patients with Parkinson’s disease frequently experience a variety of cognitive challenges. The nature and severity of these impairments and the cognitive decline rate can vary significantly among individuals and may affect attention, executive function, memory, and visuospatial skills. Digital CANTAB assessments are designed to characterize changes in patients’ cognitive profiles precisely. The assessments have been used in numerous clinical trials for Parkinson’s disease, presenting objective targets for novel treatments and assessing the safety and efficacy of new drugs in collaboration with major pharmaceutical companies.
Matthew Stork, CEO of Cambridge Cognition, commented, “We are honored that The Michael J. Fox Foundation has chosen our CANTAB assessments for its pioneering initiative. The assessments, which are highly sensitive to Parkinson’s disease progression, will support the study in gaining valuable insights that will help pave the way for new advancements in research into the disease and, ultimately, lead to new treatments.”
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in the pharmaceutical and healthcare industries.
For more about Cambridge Cognition’s digital health solutions, visit www.cambridgecognition.com
Press contact:
press@camcog.com
Author
Rob Baker
Chief of Product & Operations
Job title
Job title
